Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis

Normand E. Allaire*, Uta Griesenbach, Batsheva Kerem, John D. Lueck, Noemie Stanleigh, Yifat S. Oren

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Most people with Cystic Fibrosis (PwCF) harbor Cystic Fibrosis Transmembrane Conductance (CFTR) mutations that respond to highly effective CFTR modulators (HEM); however, a small fraction of non-responsive variants will require alternative approaches for treatment. Furthermore, the long-term goal to develop a cure for CF will require novel therapeutic strategies. Nucleic acid-based approaches offer the potential to address all CF-causing mutations and possibly a cure for all PwCF. In this minireview, we discuss current knowledge, recent progress, and critical questions surrounding the topic of Gene-, RNA-, and ASO-based therapies for the treatment of Cystic Fibrosis (CF).

Original languageAmerican English
Pages (from-to)S39-S44
JournalJournal of Cystic Fibrosis
StatePublished - Mar 2023

Bibliographical note

Funding Information:
This research was supported (in part) by grants to B.K from the Cystic Fibrosis Foundation , (grant no. KEREM15XX0 and KEREM21GO ), the Ministry of science and Technology (grant no. 3–17632 ) and the Israel Science Foundation (grant no. 2039/20 ) within the Israel Precision Medicine Partnership program and Cystic Fibrosis Foundation Research Grant ( LUECK18GO ) and NIH grant ( 1 R01 HL153988-02A1 ) to J.D.L.

Funding Information:
This paper is part of a supplement supported by the European Cystic Fibrosis Society (ECFS).

Funding Information:
John D. Lueck sits on the Scientific Advisory Boards for HcBioscience and The Cystic Fibrosis Foundation. Batsheva Karem is the CSO of SpliSense and Professor of Genetics in the Hebrew University, Jerusalem, Israel. Yifat is the Director of Discovery at SpliSense. This research was supported in part by Boehringer Ingelheim, Germany (BI), and BI was given the opportunity to review this presentation for medical and scientific accuracy as it relates to BI substances, as well as intellectual property considerations.

Publisher Copyright:
© 2023 European Cystic Fibrosis Society


  • ASO
  • Cystic Fibrosis
  • Delivery
  • Gene
  • RNA
  • Therapeutic


Dive into the research topics of 'Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis'. Together they form a unique fingerprint.

Cite this